2022
Systemic inflammation enhances stimulant-induced striatal dopamine elevation in tobacco smokers
Zakiniaeiz Y, Hoye J, Ryan Petrulli J, LeVasseur B, Stanley G, Gao H, Najafzadeh S, Ropchan J, Nabulsi N, Huang Y, Chen MK, Matuskey D, Barron DS, Kelmendi B, Fulbright RK, Hampson M, Cosgrove KP, Morris ED. Systemic inflammation enhances stimulant-induced striatal dopamine elevation in tobacco smokers. Brain Behavior And Immunity 2022, 106: 262-269. PMID: 36058419, PMCID: PMC10097458, DOI: 10.1016/j.bbi.2022.08.016.Peer-Reviewed Original ResearchConceptsEffects of LPSDopamine elevationTobacco smokersHealthy controlsSystemic inflammationDopamine systemImmune-brain interactionReward-related brain regionsAdministration of placeboAdministration of LPSSmoking statusRepeated-measures ANOVAPathophysiology of addictionDrug dosingPlaceboIndependent cohortSmokersDrug reinforcementEffect size determinationImmune systemRandomized orderBrain regionsLPSMethylphenidatePBO condition
2020
Tobacco Smoking in People Is Not Associated with Altered 18-kDa Translocator Protein Levels: A PET Study
Hillmer AT, Matuskey D, Huang Y, Nabulsi N, Ropchan J, Carson RE, O'Malley SS, Cosgrove KP. Tobacco Smoking in People Is Not Associated with Altered 18-kDa Translocator Protein Levels: A PET Study. Journal Of Nuclear Medicine 2020, 61: 1200-1204. PMID: 32005773, PMCID: PMC7413239, DOI: 10.2967/jnumed.119.237735.Peer-Reviewed Original ResearchConceptsTobacco smokingTobacco smokersTSPO levelsImmune systemPET studiesBrain immune systemBrain TSPO levelsPrimary immunocompetent cellsPrevious PET studiesTranslocator proteinTranslocator protein (TSPO) levelsInflammatory effectsImmunocompetent cellsArterial bloodTobacco smokePET scansNonsmokersSmokersRadiotracer concentrationMedium effect sizeSmokingPET imagingBrainProtein levelsSignificant differences
2019
Sex differences in amphetamine-induced dopamine release in the dorsolateral prefrontal cortex of tobacco smokers
Zakiniaeiz Y, Hillmer AT, Matuskey D, Nabulsi N, Ropchan J, Mazure CM, Picciotto MR, Huang Y, McKee SA, Morris ED, Cosgrove KP. Sex differences in amphetamine-induced dopamine release in the dorsolateral prefrontal cortex of tobacco smokers. Neuropsychopharmacology 2019, 44: 2205-2211. PMID: 31269510, PMCID: PMC6897943, DOI: 10.1038/s41386-019-0456-y.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsDA releasePositron emission tomographyD2R availabilityDorsolateral prefrontal cortexMale smokersFemale smokersTobacco smokingPrefrontal cortexAmphetamine-induced DA releaseAmphetamine-induced dopamine releaseCortical DA releaseMesocortical DA systemEffects of nicotineSmoking-related behaviorsMesolimbic dopamine systemLong-term abstinenceSex differencesGender-specific treatmentFemale nonsmokersTobacco smokersAmphetamine administrationDopamine releaseNeurochemical mechanismsNonsmokersSmokers
2017
The Effect of Treatment with Guanfacine, an Alpha2 Adrenergic Agonist, on Dopaminergic Tone in Tobacco Smokers: An [11C]FLB457 PET Study
Sandiego CM, Matuskey D, Lavery M, McGovern E, Huang Y, Nabulsi N, Ropchan J, Picciotto MR, Morris ED, McKee SA, Cosgrove KP. The Effect of Treatment with Guanfacine, an Alpha2 Adrenergic Agonist, on Dopaminergic Tone in Tobacco Smokers: An [11C]FLB457 PET Study. Neuropsychopharmacology 2017, 43: 1052-1058. PMID: 28944773, PMCID: PMC5854798, DOI: 10.1038/npp.2017.223.Peer-Reviewed Original ResearchConceptsTobacco smokersGuanfacine treatmentPositron emission tomographyTobacco smokingDA releaseDopaminergic toneDopamine releaseAmphetamine-induced DA releaseTobacco smoking cessationCortical dopamine releaseExtrastriatal brain regionsAlpha2-adrenergic agonistExtrastriatal dopamine releaseEffect of treatmentBaseline BPNDSmoking cessationReceptor radiotracerAdrenergic agonistsPET scansAnimal modelsBrain regionsEmission tomographyPET studiesDopamine signalingSmokers
2009
β2-Nicotinic Acetylcholine Receptor Availability During Acute and Prolonged Abstinence From Tobacco Smoking
Cosgrove KP, Batis J, Bois F, Maciejewski PK, Esterlis I, Kloczynski T, Stiklus S, Krishnan-Sarin S, O’Malley S, Perry E, Tamagnan G, Seibyl JP, Staley JK. β2-Nicotinic Acetylcholine Receptor Availability During Acute and Prolonged Abstinence From Tobacco Smoking. JAMA Psychiatry 2009, 66: 666-676. PMID: 19487632, PMCID: PMC2796827, DOI: 10.1001/archgenpsychiatry.2009.41.Peer-Reviewed Original ResearchMeSH KeywordsAdultAzetidinesBrainBrain MappingDominance, CerebralFemaleFollow-Up StudiesHumansImage Processing, Computer-AssistedIodine RadioisotopesMagnetic Resonance ImagingMaleMiddle AgedNicotineReceptors, NicotinicSmokingSmoking CessationSubstance Withdrawal SyndromeTobacco Use DisorderTomography, Emission-Computed, Single-PhotonConceptsWeeks of abstinenceTobacco smokingTobacco smokersAbstinent tobacco smokersAge-matched nonsmokersMagnetic resonance imaging studyMain outcome measuresCourse of abstinenceResonance imaging studyNicotinic acetylcholine receptorsMonths of abstinenceSingle photon emissionDays of abstinenceIA SPECTNonsmoker levelsClinical featuresTobacco cessationNicotine withdrawalTomography scanOutcome measuresSPECT scansSmokersReceptor availabilityAcetylcholine receptorsSmoking
2008
SPECT imaging of [123I]5-IA-85380 binding to beta2-nicotinic acetylcholine receptors in healthy smokers: Assessment of nondisplaceable uptake
Batis J, Esterlis I, Bois F, Cosgrove K, Stiklus S, Kloczynski T, McKee S, Jatlow P, O'Malley S, Seibyl J, Tamagnan G, Van Dyck C, Staley J. SPECT imaging of [123I]5-IA-85380 binding to beta2-nicotinic acetylcholine receptors in healthy smokers: Assessment of nondisplaceable uptake. NeuroImage 2008, 41: t175. DOI: 10.1016/j.neuroimage.2008.04.142.Peer-Reviewed Original Research
2006
Human Tobacco Smokers in Early Abstinence Have Higher Levels of β2* Nicotinic Acetylcholine Receptors than Nonsmokers
Staley JK, Krishnan-Sarin S, Cosgrove KP, Krantzler E, Frohlich E, Perry E, Dubin JA, Estok K, Brenner E, Baldwin RM, Tamagnan GD, Seibyl JP, Jatlow P, Picciotto MR, London ED, O'Malley S, van Dyck CH. Human Tobacco Smokers in Early Abstinence Have Higher Levels of β2* Nicotinic Acetylcholine Receptors than Nonsmokers. Journal Of Neuroscience 2006, 26: 8707-8714. PMID: 16928859, PMCID: PMC6674379, DOI: 10.1523/jneurosci.0546-06.2006.Peer-Reviewed Original ResearchConceptsNAChR availabilityNicotinic acetylcholine receptorsEarly abstinenceAbstinent smokersHuman smokersAcetylcholine receptorsExpired carbon monoxide levelsAbility of smokersHuman tobacco smokersProperties of nicotineSingle photon emissionIA-85380Agonist radiotracerUrinary cotinineTobacco smokingTobacco smokersCerebral cortexLast cigaretteNicotine withdrawalWithdrawal symptomsPrevalent subtypeTobacco smokeAddictive chemicalNicotine dependenceSmokers[I-123] 5-IA-85380 SPECT imaging of beta2-nicotinic acetylcholine receptors in recently abstinent mentally healthy and schizophrenic smokers
Staley J, Tellioglu T, Bois F, Palazzo C, McGuire-Schwartz N, Cosgrove K, van Dyck C, Tamagnan G, Seibyl J, Krystal J, D'Souza D. [I-123] 5-IA-85380 SPECT imaging of beta2-nicotinic acetylcholine receptors in recently abstinent mentally healthy and schizophrenic smokers. NeuroImage 2006, 31: t154. DOI: 10.1016/j.neuroimage.2006.04.137.Peer-Reviewed Original ResearchLongitudinal assessment of beta2-nicotinic acetylcholine receptor availability in abstinent smokers: A [I-123]5-IA-85380 SPECT imaging study
Cosgrove K, Frohlich E, Krishnan-Sarin S, O'Malley S, Bois F, Tamagnan G, Seibyl J, Staley J. Longitudinal assessment of beta2-nicotinic acetylcholine receptor availability in abstinent smokers: A [I-123]5-IA-85380 SPECT imaging study. NeuroImage 2006, 31: t155. DOI: 10.1016/j.neuroimage.2006.04.138.Peer-Reviewed Original Research